Followers | 16 |
Posts | 1295 |
Boards Moderated | 0 |
Alias Born | 11/15/2007 |
Monday, February 13, 2017 7:46:59 AM
On February 9, 2017, Genius Brands International, Inc. (the “Company”) entered into a private transaction (the “Private Transaction”) pursuant to a Warrant Exercise Agreement (the “Agreement”) with certain holders of the Company’s existing warrants (the “Original Warrants”). The Original Warrants were originally issued on November 3, 2015, to purchase an aggregate of 1,443,334 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at an exercise price of $3.30 per share and were to expire on November 3, 2020.
Pursuant to the Agreement, the holders of the Original Warrants and the Company agreed that such Original Warrant holders would exercise their Original Warrants in full and the Company would issue to each such holder new warrants, with the new warrants being identical to the Original Warrants except that the termination date of such new warrants is February 10, 2022 (the “Reload Warrants”). In addition, depending on the number of Original Warrants exercised by all holders of the Original Warrants, the Company also agreed to issue to the holders another new warrant, identical to the Original Warrant except that the exercise price of such warrant is $5.30 and such warrant is not exercisable until August 10, 2017 (the “Market Price Warrants” and together with the Reload Warrants, the “New Warrants”).
Recent GNUS News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/19/2024 09:29:58 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 04/19/2024 09:29:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/16/2024 05:00:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/16/2024 01:05:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/11/2024 09:15:56 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/10/2024 08:10:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/09/2024 07:35:12 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 04/09/2024 12:05:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/09/2024 12:00:57 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/05/2024 09:15:03 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 04/01/2024 09:02:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/23/2024 01:27:15 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/23/2024 01:24:31 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/23/2024 01:23:08 AM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 02/13/2024 10:28:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 08:34:17 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/19/2024 09:30:21 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/19/2024 05:15:24 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/12/2024 09:50:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2024 10:28:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 06:35:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 05:47:36 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/05/2024 10:09:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 09:22:26 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM